Partnership for new liver disease treatments with Ribo Partnership for new liver disease treatments with Ribo Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases
License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies
Largest European development center for biotechnology Largest European development center for biotechnology Boehringer Ingelheim inaugurates largest European development center for biotechnology
Boehringer Olaf Scholz break ground for innovation center Boehringer Olaf Scholz break ground for innovation center Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
LastMile increases access to veterinary care in Africa LastMile increases access to veterinary care in Africa Boehringer Ingelheim’s LastMile initiative reaches over 40,000 smallholder farmers in Sub-Saharan Africa increasing access to veterinary medicine
Blue internal teat sealant now in dairy mastitis portfolio Blue internal teat sealant now in dairy mastitis portfolio Boehringer Ingelheim adds blue internal teat sealant to its dairy mastitis portfolio
environmental sustainability commitments environmental sustainability commitments On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
BI_X_Shanghai BI_X_Shanghai Boehringer Ingelheim opens a second branch of its digital lab in Shanghai
Behavioral science to improve cattle well-being Behavioral science to improve cattle well-being Boehringer Ingelheim kicks off a project based on behavioral science to improve cattle well-being
Acquisition expands research in cancer immunology Acquisition expands research in cancer immunology Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
EURORDIS Award EURORDIS Award EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020
Classical Swine Fever live vaccine approved in China Classical Swine Fever live vaccine approved in China Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
FOYA_Shanghai FOYA_Shanghai Boehringer Ingelheim’s commercial manufacturing facility in Shanghai has been awarded as “Facility of the Year”
Henke-Sass Wolf develop needle free device Henke-Sass Wolf develop needle free device Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
Official partner to Cat Care for Life Official partner to Cat Care for Life Boehringer Ingelheim announces its new partnership with the CatCareforLife program.
Partnering with Constantia Flexibles for augmented reality Partnering with Constantia Flexibles for augmented reality Boehringer Ingelheim partnered with Constantia Flexibles to provide an innovative packaging solution which enhances the Nutraxin packaging with augmented reality features.
Awards & International Recognition| Bioxcellence | Boehringer Ingelheim Awards & International Recognition| Bioxcellence | Boehringer Ingelheim Explore Bioxcellence's global recognition, showcasing our prestigious awards & certifications. Witness our commitment to excellence in biopharmaceuticals!
How Boehringer Ingelheim is Supporting Grass Roots Innovation How Boehringer Ingelheim is Supporting Grass Roots Innovation Our Grass Roots activities support life-science innovators with mentoring and networking opportunities.
Biopharmaceutical Contract Manufacturing | Bioxcellence | Boehringer Ingelheim Biopharmaceutical Contract Manufacturing | Bioxcellence | Boehringer Ingelheim Meet BioXcellence - your trusted partner for top-quality biopharmaceutical development & manufacturing. Experience our world-class service. Contact us.
About Boehringer Ingelheim Partnering Days About Boehringer Ingelheim Partnering Days Find out more about our partnering days and how we can work together to accelerate your science
opening-solids-launch-fabrik opening-solids-launch-fabrik Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
New partnership to develop schizophrenia treatments New partnership to develop schizophrenia treatments Boehringer Ingelheim partners with Sosei Heptares to develop next generation schizophrenia treatments
Arti-cell Forte stem cell-based veterinary product Arti-cell Forte stem cell-based veterinary product Boehringer Ingelheim launches the first-ever registered stem cell-based veterinary medicine
IL-11 inhibitor antibody clinical development launched IL-11 inhibitor antibody clinical development launched Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
commitments to sustainable development commitments to sustainable development On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities